When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ARQT - Arcutis enrolls last patient in mid-stage ARQ-154 trial for seborrheic dermatitis
Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics (ARQT+3.4%) has completed enrollment of its Phase 2 proof of concept clinical trial evaluating roflumilast foam as a potential treatment for seborrheic dermatitis, a chronic or recurrent skin condition that causes red patches and persistent itch.
More news on: Arcutis Biotherapeutics, Inc., Healthcare stocks news,